Full Text
PCN32 ECONOMIC EVALUATION OF SUNITINIB, SORAFENIB, BEVACIZUMAB/ INTERFERON ALPHA AND TEMSIROLIMUS IN FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ISRAEL

Abstract

Authors

D Greenberg

Back to Volume 12, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×